Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced that Astellas Pharma Inc. (TSE: ...
Following a research collaboration established in 2021, Astellas Pharma has reached an agreement to license a Dyno ...
Dyno Therapeutics, a privately-held US genetic technologies company applying artificial intelligence (AI) to solve the grand ...
The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...
The last time I wrote about Abeona Therapeutics (ABEO) it was in a Seeking Alpha article entitled "Abeona: BLA Resubmission of Pz-Cel Gets Ball Rolling Towards Other Milestones." With respect to this ...
Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, has expanded its product offering, with the launch of the AAVX Total Capsid Quantification ...
NORWICH, England & CHICAGO--(BUSINESS WIRE)--Ikarovec Ltd, which is developing dual-pathway gene therapies for vision-threatening retinal diseases, and VectorBuilder, a global leader in gene delivery ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results